Literature DB >> 17164688

Teicoplanin population pharmacokinetic analysis in hospitalized patients.

Dolors Soy1, Ester López, Josep Ribas.   

Abstract

The goal of this study was to build a population pharmacokinetic (PK) model to characterize the population PK parameters in our hospitalized patients. Teicoplanin serum concentrations from clinical routine were used. Antibiotic dose history and blood collection times were recorded and analyzed with NONMEM-V. Demographic and biologic data creatinine clearance (CLcr), weight (WT), and albumin (Alb) were tested for inclusion as covariates in the basic model. Intraindividual and residual variability were modeled. One hundred seven sparse samples (mainly trough levels), from 79 patients, were included. A 2-compartment PK model characterized by clearance (CL), central compartment volume of distribution (Vc), intercompartment clearance, and steady-state volume of distribution (VSS) with first-order elimination adequately described the data. CLcr and WT significantly influenced teicoplanin CL (CL = 0.57[0.15]*(1+0.0048[0.39]*(CLcr - averageCLcr)*WT) L/h). VSS was not affected by any covariate (VSS = 50.2[0.13]L). A negative trend between Alb and individual VSS estimates was observed without statistical significance. In a new data set, bias and precision resulted in mean values of -3.24% and 9.42%, respectively. In conclusion, CLcr and WT are significant covariates on teicoplanin CL. Results from predictive accuracy and precision show the usefulness of this model for implementation in a therapeutic drug monitoring program in the near future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17164688     DOI: 10.1097/01.ftd.0000249942.14145.ff

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?

Authors:  A Kontou; K Sarafidis; O Begou; H G Gika; A Tsiligiannis; K Ogungbenro; A Dokoumetzidis; E Agakidou; E Roilides
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

2.  Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.

Authors:  Wei Zhao; Daolun Zhang; Thomas Storme; André Baruchel; Xavier Declèves; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2015-09-05       Impact factor: 4.335

Review 3.  The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.

Authors:  Marta Ulldemolins; Jason A Roberts; Jordi Rello; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2011-02       Impact factor: 6.447

4.  Population Pharmacokinetics and Dose Optimization of Teicoplanin during Venoarterial Extracorporeal Membrane Oxygenation.

Authors:  Jin Wi; Hayeon Noh; Kyoung Lok Min; Seungwon Yang; Byung Hak Jin; Jongsung Hahn; Soo Kyung Bae; Jiseon Kim; Min Soo Park; Donghoon Choi; Min Jung Chang
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 5.  Contribution of Population Pharmacokinetics of Glycopeptides and Antifungals to Dosage Adaptation in Paediatric Onco-hematological Malignancies: A Review.

Authors:  Stéphanie Leroux; Françoise Mechinaud-Heloury; Evelyne Jacqz-Aigrain
Journal:  Front Pharmacol       Date:  2021-04-01       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.